Literature DB >> 27935847

Structure-based development of PDEδ inhibitors.

Pablo Martín-Gago1, Eyad Kalawy Fansa2, Alfred Wittinghofer2, Herbert Waldmann1.   

Abstract

The prenyl binding protein PDEδ enhances the diffusion of farnesylated Ras proteins in the cytosol, ultimately affecting their correct localization and signaling. This has turned PDEδ into a promising target to prevent oncogenic KRas signaling. In this review we summarize and describe the structure-guided-development of the three different PDEδ inhibitor chemotypes that have been documented so far. We also compare both their potency for binding to the PDEδ pocket and their in vivo efficiency in suppressing oncogenic KRas signaling, as a result of the inhibition of the PDEδ/KRas interaction.

Entities:  

Keywords:  KRas; PDEδ; small molecules; structure-based design; structure-property-relationships

Mesh:

Substances:

Year:  2017        PMID: 27935847     DOI: 10.1515/hsz-2016-0272

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.

Authors:  Menglu Guo; Shipeng He; Junfei Cheng; Yu Li; Guoqiang Dong; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2022-01-12       Impact factor: 4.345

2.  Mechanistic insights into the role of prenyl-binding protein PrBP/δ in membrane dissociation of phosphodiesterase 6.

Authors:  Bilal M Qureshi; Andrea Schmidt; Elmar Behrmann; Jörg Bürger; Thorsten Mielke; Christian M T Spahn; Martin Heck; Patrick Scheerer
Journal:  Nat Commun       Date:  2018-01-08       Impact factor: 14.919

3.  From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.

Authors:  Mahsa Saliani; Razieh Jalal; Mohammad Reza Ahmadian
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

4.  Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models.

Authors:  Long Chen; Jing Zhang; Xinjing Wang; Yu Li; Lu Zhou; Xiongxiong Lu; Guoqiang Dong; Chunquan Sheng
Journal:  Acta Pharm Sin B       Date:  2021-07-19       Impact factor: 11.413

Review 5.  Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.

Authors:  Haiying Lu; Qiaodan Zhou; Jun He; Zhongliang Jiang; Cheng Peng; Rongsheng Tong; Jianyou Shi
Journal:  Signal Transduct Target Ther       Date:  2020-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.